Thus, the presence of either CD28% down-regulation or low DLCO%p values, as simultaneous, combined, cross-sectional ascertainments, would seemingly identify a large proportion of the patients within an IPF cohort who are at greatest risk for serious adverse events within the next few months. Here, CD28 is linked to idiopathic pulmonary fibrosis.